* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Dish of the Day
Admissions:
None
Delistings:
None
What’s baking in the oven?
Market Movers:***
14 January: GlobalData (DATA.L), the data, insight, and technology Company expects to submit its application to move to the Main Market from AIM and to take place on 5 March.
Banquet Buffet****
Aptamer Group 0.95p £25.62m (APTA.L)
The developer of next-generation synthetic binders for the life sciences industry reports a new TrueAmp Library Preparation Kit is using Aptamer's proprietary Optimer binders. These are being used as an enabling technology for stability at room temperature, the specialised TrueAmp polymerase maximises coverage across typically hard-to-sequence regions of the genome - while maintaining high accuracy during DNA copying. This product launch demonstrates the real-world value of the Optimer technology in enabling market-ready products.
Fulcrum Metals 8.75p £12.10m (FMET.L)
The pioneer user of innovative cyanide-free technologies to recover precious and critical metals from historic mine waste initiates a Pilot Plant Scoping Study. The Study with Test Design Implement Solutions (TDI) is for upscaling work at its Teck Hughes and Sylvanite tailings projects in Kirkland Lake, Ontario. Fulcrum has commissioned TDI to undertake the Study to identify the best way to advance from successful laboratory scale tests to a pilot-scale operation. This study will provide Fulcrum with a framework to implement a standalone pilot plant to upscale from laboratory to pilot tests for all Fulcrum projects, and for potential asset partners.
Gattaca 126.50p £38.45m GATC.L)
The specialist staffing solutions business updates on trading for its Interims to January 2026. The Net Fee Income (NFI) is expected to increase to £21.1m from H125’s £18.0m driven by strong contract performance across core growth sectors. The Like-for-Like contract NFI increased by 13% YoY, reflecting increased activity levels in core sectors. Total Group sales headcount was reduced by 6% YoY. The Group continued to focus on operational efficiency and disciplined resource allocation, while maintaining investment in target sectors. A reduction in net cash to £13m from £16.8m reflects acquisitions costs and dividend payments. The guidance for FY26 adjusted profit before tax is expected to be £4.5m as the Group is trading ahead of expectations after strategic investments in growth opportunities.
Gelion 19.00p £42.44m (GELN.L)
The advanced battery materials Company updates on technological progress and strategic partnerships. Initial pouch cells incorporating Gelion's NES CAM have been successfully manufactured by TDK with early test results meeting the Company's expectations. Active discussions are progressing with multiple global partners across a range of applications and geographies. Samples of its proprietary sulfur CAM formulations have been delivered to both TDK in Japan and to QinetiQ in the UK. The Australian Renewable Energy Agency (ARENA) has increased the total project budget from c.£4.8m to c.£5.3m. The Company is focused on converting the strong pipeline of discussions into formal partnerships.
IG Design Group 61.50p £46.94m (IGR.L)
The designer, innovator and manufacturer across various celebration and creative categories updates on trading. The Board now anticipates the FY to March 2026 being at the upper end of the previously stated guidance and above current market consensus. FY2026 revenues are anticipated to be c.$280-285m, with final quarter sales expected to be in line with the prior year. The adjusted operating margin, however, is expected to be at the higher end at c.4%. Together with higher interest income, this is expected to result in the adjusted profit exceeding current market expectations. The cash performance during the year has been particularly strong, with full-year net cash expected to be c.$55-60m, which is c.$15-20m ahead of market expectations. Looking beyond FY2026, the Board's outlook remains consistent with prior guidance. The CEO recruitment process remains underway.
Kefi Gold and Copper 1.58p £160.4m (KEFI.L)
The exploration and development Company focused on gold and copper deposits in the highly prospective Arabian-Nubian Shield gave an update on the Tulu Kapi Gold Project in Ethiopia (TKGM). It announces a $20m equity-ranking-royalty with Chancery Royalty Limited. This is a key final part of the $340m financing package for the Company's high-grade/high-recovery Tulu Kapi Gold Project. It has been creatively structured with Chancery Royalty to be an equity-risk ranking royalty and is payable alongside distributions made by TKGM to its shareholders. Field teams and contractors have been mobilised and a 'Ground Breaking Ceremony' organised.
Renalytix 4.38p £24.47m (RENX.L)
The precision medicine diagnostics Company whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, updates on Interim Trading to December 2025. Revenues of $1.6m was lower than expected due to longer lead times and complexities with larger healthcare systems. The FY June 2026 revenue guidance of $4m, which is up 33% YoY, is being reiterated. There were three new integrations implemented in H1 FY26, compared to one in FY25, which will accelerate H2 revenue. The Company continues to focus on implementing cost reduction initiatives and maintained a cash balance of around $6m.
Red Rock Resources 0.03p £2.45m (RRR.L)
The natural resource exploration and development Company with interests in gold, base and battery metals, and hydrocarbons principally in Africa and Australia announces an update. In the Democratic Republic of Congo, the judgment and conclusion of the litigation proceedings remain pending, and the Company is confident that its position will be upheld. The Company has recently signed an NDA and started its due diligence assessment involving external consultants of a privately held potential copper-cobalt mining project in the Kambove region of Katanga. Other licence opportunities are being reviewed with enough opportunities to identify and access quality projects.
TPXimpact Holdings 29.00p £25.22m (TPX.L)
The technology-enabled services Company focused on people-powered digital transformation wins a 2-year digital transformation £22m contract with NHS England under the Digital Outcomes 6 (DOS6) framework. The Company will deliver services across Maternity, Neonatal and School-Age Vaccinations, supporting three end-to-end vaccination pathways across multiple care settings, including GP practices, schools and community environments. The CEO states the award shows the Company can operate at scale on complex government programmes.
Zinc Media Group 48.00p £11.46m (ZIN.L)
The television and content production Group report a Trading update for the year ending December 2025. The Group expects to report revenue of £41m which is growth of 27%, and an Adjusted EBITDA of £1.9m which is comparatively 27% ahead. 2026 has started positively by securing £3m of new business including an international returning TV series and there are £21m of projects secured or highly advanced in the pipeline. Additionally, the Group is in advanced discussions over commissions worth a further £10m and is in early-stage discussions with eight large projects each with a value of over £1m which could be delivered later this year. The Group states that it remains on track to deliver its medium-term targets of £50m revenue and £5m EBITDA.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.